Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Rating Reiterated by Cantor Fitzgerald

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM)‘s stock had its “overweight” rating reaffirmed by analysts at Cantor Fitzgerald in a research report issued on Tuesday, Benzinga reports. They presently have a $21.00 price objective on the biotechnology company’s stock. Cantor Fitzgerald’s target price would indicate a potential upside of 169.23% from the company’s current price.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Actinium Pharmaceuticals in a research report on Monday. StockNews.com raised Actinium Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. Finally, Maxim Group lifted their price objective on Actinium Pharmaceuticals from $20.00 to $30.00 and gave the stock a “buy” rating in a research report on Tuesday, March 19th. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $25.72.

Actinium Pharmaceuticals Stock Up 5.7 %

Actinium Pharmaceuticals stock traded up $0.42 during mid-day trading on Tuesday, hitting $7.80. The company’s stock had a trading volume of 95,162 shares, compared to its average volume of 319,378. Actinium Pharmaceuticals has a 12 month low of $4.00 and a 12 month high of $9.86. The company has a market capitalization of $229.32 million, a PE ratio of -4.28 and a beta of 0.01.

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) last issued its earnings results on Friday, March 29th. The biotechnology company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.21. The company had revenue of $0.08 million for the quarter. As a group, equities analysts expect that Actinium Pharmaceuticals will post -1.87 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Sanders Morris Harris LLC purchased a new position in shares of Actinium Pharmaceuticals during the 1st quarter worth $78,000. Creative Financial Designs Inc. ADV grew its holdings in Actinium Pharmaceuticals by 19.1% during the fourth quarter. Creative Financial Designs Inc. ADV now owns 19,800 shares of the biotechnology company’s stock valued at $101,000 after purchasing an additional 3,175 shares during the period. Finally, Brandywine Global Investment Management LLC purchased a new stake in Actinium Pharmaceuticals in the third quarter worth about $1,033,000. 27.50% of the stock is owned by hedge funds and other institutional investors.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center.